Why 2011 Could Be a Big Year for Pharmaceutical M&A
Apr 24, 2011 | Posted by: roboblogger | Full story: Seeking Alpha
Just a couple of weeks after Gilead Sciences announced that it would be raising the prices of its leading HIV drugs, the company issued first quarter earnings numbers that were significantly below analyst expectations.
Good the bastards cause as much harm as good with their poison product. I hope they go bankrupt.
|Temasek Bought Shares of Gilead, 21Vianet Group...||Feb 15||GILEAD Deferauding Drug||1|
|Health Canada Issues Notice of Compliance for S...||Feb 15||Gilead Defrauding HEP C||1|
|FDA advisors back new Hepatitis C drug||Oct '13||WARNING FDA APPROVED||1|
|Gilead's Sofosbuvir for Hepatitis C Meets Prima... (Feb '13)||Feb '13||Axel||1|
|HIV11: Stribild Matches Efficacy and Tolerabili... (Jan '13)||Jan '13||kmc2749||1|
|FDA approves first pill to help prevent HIV (Jul '12)||Jul '12||k-wire||3|
|FDA Panel OKs Truvada for HIV Prevention (May '12)||May '12||KittenKoder||5|